Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A rare inherited genodermatosis characterized by chronic infection with human papillomavirus (HPV) leading to polymorphous cutaneous lesions and high risk of developing non melanoma skin cancer.
Features include very common findings: Seborrheic dermatitis, Recurrent skin infections, Abnormality of the immune system, and Papule and others; and common findings: Hypopigmented skin patches and Multiple cafe-au-lait spots. 11 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Skin | 6 | Seborrheic dermatitis, Hypopigmented skin patches, Recurrent skin infections |
Phenotype severity distribution: 7 very common features, 2 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for epidermodysplasia verruciformis.
45 publications have been identified in PubMed for epidermodysplasia verruciformis. Kisho has analyzed 20 by research type. Research spans Case Report / Case Series (60%), Review / Meta-Analysis (25%), and Other (10%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 12 | 60% |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 8:41 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Blood and immune system |
1 |
Recurrent skin infections |
Immune system | 1 | Abnormality of the immune system |
Research summaries
5 |
25% |
Other research | 2 | 10% |
Laboratory research | 1 | 5% |
Shen A (2026). [PMID: 41649263](https://pubmed.ncbi.nlm.nih.gov/41649263/). *Int J Dermatol*. [Review / Meta-Analysis]
Biglari S (2026). [PMID: 41609194](https://pubmed.ncbi.nlm.nih.gov/41609194/). *J Eur Acad Dermatol Venereol*. [Other]
Momin NS (2026). [PMID: 41827466](https://pubmed.ncbi.nlm.nih.gov/41827466/). *J Clin Med*. [Review / Meta-Analysis]
Zhang Z (2026). [PMID: 41783065](https://pubmed.ncbi.nlm.nih.gov/41783065/). *Front Med (Lausanne)*. [Other]
Kassang P (2025). [PMID: 41250775](https://pubmed.ncbi.nlm.nih.gov/41250775/). *Case Rep Dermatol Med*. [Case Report / Case Series]
Azhar S (2025). [PMID: 40125015](https://pubmed.ncbi.nlm.nih.gov/40125015/). *Skin Health Dis*. [Case Report / Case Series]
Wong M (2025). [PMID: 39813296](https://pubmed.ncbi.nlm.nih.gov/39813296/). *PLoS Pathog*. [Basic Science / Preclinical]
Sandoval-Clavijo A (2025). [PMID: 40075744](https://pubmed.ncbi.nlm.nih.gov/40075744/). *Cancers (Basel)*. [Review / Meta-Analysis]
Boutaarourt M (2025). [PMID: 40666071](https://pubmed.ncbi.nlm.nih.gov/40666071/). *Oxf Med Case Reports*. [Case Report / Case Series]
Zheng J (2025). [PMID: 40257968](https://pubmed.ncbi.nlm.nih.gov/40257968/). *Photobiomodul Photomed Laser Surg*. [Case Report / Case Series]
AI-curated news mentioning epidermodysplasia verruciformis
Updated Mar 7, 2026
A recent study published in PubMed explores acquired epidermodysplasia verruciformis in patients undergoing iatrogenic immunosuppression. This research highlights the implications of immunosuppressive therapies on the development of this rare skin condition.